Compare Stocks: IPHA, WVE, GERN, and DSGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$15.03 -3.2%	$14.08	$5.28 ▼ $17.25	$971.89M	1.66	553,544 shs	376,169 shs
GERN Geron	$1.51 -5.0%	$1.46	$1.04 ▼ $2.01	$1.02B	0.61	9.55 million shs	14.23 million shs
IPHA Innate Pharma	$2.11 -2.8%	$1.95	$1.17 ▼ $2.71	$242.43M	0.34	425,318 shs	10,891 shs
WVE WAVE Life Sciences	$4.70 -3.7%	$5.65	$4.64 ▼ $21.73	$961.59M	-1.3	3.57 million shs	6.16 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	-3.22%	-1.44%	+13.86%	+41.13%	+152.18%
GERN Geron	-5.03%	-1.31%	+12.27%	+29.06%	+7.86%
IPHA Innate Pharma	-2.76%	-5.38%	+18.21%	+23.39%	+4.46%
WVE WAVE Life Sciences	-3.69%	-8.91%	-21.67%	-17.98%	-41.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$15.03 -3.2%	$14.08	$5.28 ▼ $17.25	$971.89M	1.66	553,544 shs	376,169 shs
GERN Geron	$1.51 -5.0%	$1.46	$1.04 ▼ $2.01	$1.02B	0.61	9.55 million shs	14.23 million shs
IPHA Innate Pharma	$2.11 -2.8%	$1.95	$1.17 ▼ $2.71	$242.43M	0.34	425,318 shs	10,891 shs
WVE WAVE Life Sciences	$4.70 -3.7%	$5.65	$4.64 ▼ $21.73	$961.59M	-1.3	3.57 million shs	6.16 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	-3.22%	-1.44%	+13.86%	+41.13%	+152.18%
GERN Geron	-5.03%	-1.31%	+12.27%	+29.06%	+7.86%
IPHA Innate Pharma	-2.76%	-5.38%	+18.21%	+23.39%	+4.46%
WVE WAVE Life Sciences	-3.69%	-8.91%	-21.67%	-17.98%	-41.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	9.78% Upside
GERN Geron	2.20	Hold	$4.00	164.90% Upside
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	215.96% Upside
WVE WAVE Life Sciences	2.81	Moderate Buy	$22.31	374.73% Upside

Current Analyst Ratings Breakdown

Latest IPHA, WVE, GERN, and DSGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	IPHA Innate Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	IPHA Innate Pharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy ➝ Outperform
8/11/2026	IPHA Innate Pharma	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00
8/10/2026	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $7.00
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00
8/3/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	WVE WAVE Life Sciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $22.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
GERN Geron	$183.88M	5.28	N/A	N/A	$0.34 per share	4.44
IPHA Innate Pharma	$10.19M	23.13	N/A	N/A	($0.26) per share	-8.12
WVE WAVE Life Sciences	$42.73M	21.67	N/A	N/A	$2.30 per share	2.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	25.17	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
IPHA Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/17/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest IPHA, WVE, GERN, and DSGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/17/2026	Q2 2026	IPHA Innate Pharma	-$0.2946	N/A	N/A	N/A	$6.35 million	N/A
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	18.86	18.86
GERN Geron	0.55	6.91	5.16
IPHA Innate Pharma	N/A	1.27	1.27
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
GERN Geron	73.71%
IPHA Innate Pharma	0.16%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	17.10%
GERN Geron	1.71%
IPHA Innate Pharma	31.89%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
GERN Geron	70	642.47 million	631.49 million	Optionable
IPHA Innate Pharma	220	111.72 million	76.09 million	Not Optionable
WVE WAVE Life Sciences	240	197.05 million	149.17 million	Optionable

IPHA, WVE, GERN, and DSGN Headlines

Recent News About These Companies

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Analysts

34 minutes ago | americanbankingnews.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from Analysts

35 minutes ago | marketbeat.com

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

September 3 at 4:05 PM | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 4.3% - Time to Sell?

September 2 at 12:19 PM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Reaches New 12-Month Low - What's Next?

August 31, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold"

August 21, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in Stock

August 14, 2026 | insidertrades.com

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 13, 2026 | marketbeat.com

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

August 13, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

August 13, 2026 | marketbeat.com

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

August 13, 2026 | 247wallst.com

Wave Life Sciences: An Fairly Valued RNA Opportunity

August 12, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened

August 12, 2026 | marketbeat.com

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

August 11, 2026 | marketbeat.com

Wave Life Sciences Completes Redomiciliation to Delaware

August 10, 2026 | finance.yahoo.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

August 10, 2026 | marketbeat.com

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026 | globenewswire.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 10, 2026 | marketbeat.com

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

August 7, 2026 | finance.yahoo.com

WAVE Life Sciences Ltd. $WVE Shares Purchased by Renaissance Technologies LLC

August 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, WVE, GERN, and DSGN Company Descriptions

Design Therapeutics NASDAQ:DSGN

$15.03 -0.50 (-3.22%)

As of 09/3/2026 04:00 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Geron NASDAQ:GERN

$1.51 -0.08 (-5.03%)

As of 09/3/2026 04:00 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Innate Pharma NASDAQ:IPHA

$2.11 -0.06 (-2.76%)

As of 09/3/2026 04:00 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

WAVE Life Sciences NASDAQ:WVE

$4.70 -0.18 (-3.69%)

As of 09/3/2026 04:00 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, WVE, GERN, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, WVE, GERN, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, WVE, GERN, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, WVE, GERN, and DSGN Company Descriptions

Design Therapeutics NASDAQ:DSGN

Geron NASDAQ:GERN

Innate Pharma NASDAQ:IPHA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, WVE, GERN, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, WVE, GERN, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, WVE, GERN, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, WVE, GERN, and DSGN Company Descriptions

Design Therapeutics NASDAQ:DSGN

Geron NASDAQ:GERN

Innate Pharma NASDAQ:IPHA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools